IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer August 25, 2026
FDA Fast Track Designation Granted to ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma August 25, 2026
Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer August 25, 2026
FDA written feedback provides alignment on a potential pivotal Part B expansion of the ongoing REO 033 study August 25, 2026
Patient enrollment completed in Ph 3 TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer August 20, 2026
FDA Fast Track designation for spevatamig in advanced and metastatic biliary tract carcinoma August 20, 2026
FAILED TRIAL: Ph 2 DeFianCe study of sirexatamab (DKN-01) in 2L CRC did not meet primary endpoint of PFS improvement August 20, 2026
ACR-2316 advances into dose expansion portion of Ph 1/2 study in SCLC, squamous NSCLC, lung adenocarcinoma (adNSCLC), endometrial, cervical, and GEJ cancers August 11, 2026
First Patient Dosed in Registrational Study of IBI363/TAK-928 in Combination with Bevacizumab in Late-Line Advanced CRC in China August 11, 2026
CRL issued for ongoing ITM-11 NDA citing CMC and third-party commercial facility inspection-related items August 11, 2026
Olomorasib receives FDA Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer August 5, 2026
IDE892 Initiates Part 2 Monotherapy Expansion in Ph 1/2 Study in MTAP-Deleted Pancreatic & Lung Cancers August 5, 2026
Final subject received last dose of Ampligen (rintatolimod) in Ph 2 DURIPANC trial of Ampligen + Imfinzi for the treatment of metastatic pancreatic cancer August 5, 2026
IND Application for Ph 1b/2 Opamtistomig Combo in Metastatic Colorectal Cancer Approved August 5, 2026
BeOne Medicines Expands U.S. Manufacturing with More Than $1 Billion Investment to Advance Cancer Medicines July 28, 2026
Sonesitatug vedotin demonstrated statistically significant OS improvement in 2L+ CLDN18.2-positive advanced gastric/GEJ cancers July 28, 2026
FDA accepts NDA for Daraxonrasib for Review for Previously Treated Metastatic Pancreatic Cancer July 28, 2026
CTA and supply agreement between Phanes & Merck to evaluate spevatamig, KEYTRUDA & chemo combo for treatment of biliary tract cancer expanded July 28, 2026
